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What is a drug, and who says what a drug is? This is a tricky area. For this talk I use the concept 
that a drug is an exogenous substance, something 
that comes from outside a person, goes into them 
and produces physiological changes. 
Regulation and control
In the last 40 years we in the UK have developed a 
way of regulating drugs using a complex legislative 
framework. There are two major acts of parliament 
regulating drugs. First, there is the Medicines Act 
1968, which is essentially monitored and acted upon 
by the Medicines and Healthcare Regulatory Agency 
(MHRA), and second, there is the Misuse of Drugs 
Act 1971, which comes under the remit of the Home 
Ofﬁ ce (see Figure 1).  Thus, recreational psychoactive 
substances are controlled by Home Ofﬁ ce legislation. 
There are a number of other substances that are 
popularly used and cause harm whose risks fall 
outside these two control mechanisms. For example, 
alcohol and tobacco are essentially regulated foods 
or commodities, while solvents, which kill about 
ten people a year in the UK through inhaling, are 
regulated at the point of sale according to the age 
of the person buying the solvent. Other drugs are 
also used. Coffee is one of the most popular drugs 
in the UK and throughout the world. Khat, another 
plant-based stimulant (akin to strong coffee) that is 
chewed rather than pre-processed as a drink, is used 
particularly in the Horn of Africa but also by migrants 
from that region in the UK. Coffee and khat have 
relatively unregulated sales.
Different drugs come under different areas of control 
and some are under no control at all.  As shown in 
Figure 1, there is overlap between how some drugs 
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FIGURE 1 . THE CURRENT LEGISLATIVE FRAME WORK
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are controlled – many of those controlled under the 
Misuse of Drugs Act are also controlled under the 
Medicines Act. In fact, most of the drugs controlled 
by the Misuse of Drugs Act are also used clinically.
The Misuse of Drugs Act essentially divides drugs 
into three classes: A, B and C. The thinking behind 
this Act was to try to produce a system of relative-
based harm, so that drugs could be scaled against 
each other and then put into one of the three classes 
that controlled penalties. The idea was that this 
would be a ﬂ exible system: as evidence of greater or 
lesser harm emerged, drugs could be moved up and 
down the scale. That was the original intention, but 
the Act has become rather ossiﬁ ed since then, and 
there has been very little movement, and especially 
very little downward movement.  
Table 1 illustrates drug classes (A–C) and schedules 
(1–4) under the Misuse of Drugs Act. The majority 
of drugs speciﬁ ed under this Act are used clinically, 
and the schedules tell you which drugs can be used 
for clinical purposes. If they are not used clinically, 
they are treated as illegal but can be used clinically. 
Schedules 2, 3 and 4 include drugs which have a 
clinical use. Some in schedule 1 are not currently 
used medically but they have been in the past. 
For example, cocaine was commonly used to treat 
terminal cancer; MDMA (ecstasy) has had some utility 
and is being resurrected as a treatment to augment 
psychotherapy in severe forms of post-traumatic 
stress disorder. Cannabis was once a medicinal 
product, then was made illegal, and now seems 
likely to return as a medicinal product in the UK as in 
many other countries. Then there are drugs that have 
never been used medically and have no medical 
use. These are in schedule 1: crack cocaine, LSD and 
psilocybin (the active component of mushrooms). 
A more recent drug which is in the process of being 
made illegal is BZP (benzylpiperazine); although BZP 
was designed as a medicine, it was deemed not safe 
enough to be used in this way.  
Since 1971 there has been some movement of drugs 
between classiﬁ cations and schedules. Drugs such as 
ketamine and GHB have recently come under control 
of the Act and new drugs introduced under the Act. 
Methylamphetamine has moved from class B to 
class A. Psilocybin (as psychedelic mushrooms) was 
outside the Act but has come into class A in the last 
couple of years, and Benzylpiperazine will become 
class C shortly. Cannabis has had an interesting 
rotation; over the past six years it has gone from B 
(with some forms as A) to C, and then recently back 
to B.   
Why does it matter where drugs are covered by 
the Act?  The key point about classiﬁ cation is that 
the class determines the penalties. Essentially you 
can divide the penalties into two kinds: those for 
possession (the penalty applying to the individual 
who has the drug for personal use), and penalties 
for those who have the drug for selling on to others, 
importation, supply, etc. The maximum penalties 
for possession are seven years in prison for a class 
A drug, ﬁ ve years for class B, and two years for class 
C. For supply, the penalties are, respectively, life, 14 
years and 14 years.  
I want to make two observations about this. The 
ﬁ rst is that taking a drug is not currently illegal in 
this country. There have been attempts to make it 
so, but the most reasoned arguments suggest that 
this is not a particularly useful way of reducing 
harm. You can impose civil or employment 
penalties for detecting drugs, particularly if you 
Schedules Class A Class B Class C
2-3-4. Medicines Opioids 
Metamphetamine 
i.v. amphetamine
Amphetamines / Barbiturates Benzodiazepines 
Ketamine 
GHB 
Buprenorphine 
Steroids 
Growth Hormone
1. Not currently 
medically recognised
Cocaine / MDMA Cannabis Clenbuterol
1. Never medical Crack cocaine 
LSD 
Psilocybin (mushrooms)
Benzylpiperazine
TABLE 1 . HOW THE MISUSE OF DRUGS ACT WORKS
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FIGURE 2 . POLICY FORMATION
work in areas where drugs may cause impairment 
to performance. This is currently a huge issue in the 
military, where use of drugs outside what you might 
call ‘active’ employment is causing great tension 
and leading to the potential loss of very highly 
trained personnel. My second observation is that 
it has not always been the case that the maximum 
penalty for supplying a class C drug has been 14 
years; at one point it was seven years. In a kind of 
tit-for-tat, when cannabis was downgraded from 
class B to C, the government decided to bolster 
the potential penalties for possession to try to 
minimise what it considered might be harms from 
downgrading, and thus changed the penalty from 
seven years to 14 years for supply.  
Drug policy
Formulating policy in relation to drugs is obviously 
quite a difﬁ cult thing to do. I comment on it, as I 
always have, from the perspective of a psychiatrist 
who is interested in drugs and drugs and the brain. 
In many ways, that’s how the Advisory Council on 
the Misuse of Drugs (ACMD) covers it. We have a 
range of expertise on the Council; we’re very strong 
in terms of chemistry and pharmacology, and 
psychology; and we have a deﬁ nite knowledge, 
interest and responsibility to look at social harms as 
well. We provide one arm of the policy formulating 
perspective. In addition, there are a number of 
other agencies, organisations and individuals who 
contribute to policy formation. 
There are also what might be described as formal 
inputs through public consultation, not so much 
with the general public, but with interested 
public organisations such as the British Chemical 
Industry. There are also international partners – we 
have signed up to international treaties – which 
determine that, in essence, the UK follows United 
Nations policy on drugs. This can be quite a tough 
constraining inﬂ uence on how countries regulate 
drugs (although some countries, such as the 
Netherlands, have managed to be more ﬂ exible in 
the way they deal with drugs, even though they still 
sign up to the international conventions).  
Then, of course, there are other factors feeding into 
political decisions about drugs: what the general 
public thinks (or is thought to think); and then there’s 
the media. Figure 2 shows the range of inﬂ uences 
that impact on the policy formation process with 
regard to drugs and their misuse. 
In recent years the whole process of determining 
drug classiﬁ cation has become quite complex and 
highly politicised. 
External pressures Inputs to decision making pressures
Public
Media
Expert 
evidence
Lobby/pressure 
groups
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Formal public 
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International 
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Cannabis – a potent problem
I am going to focus on cannabis because it is the 
only drug that has been downgraded in the whole 
history of the Act, an interesting point in itself. 
The issues relating to cannabis pose a challenge 
to whether the Act is working as it was originally 
intended. 
The ACMD was requested by the Home Secretary 
in 2007 to review the status of cannabis because: 
‘Though statistics show that cannabis use has fallen 
signiﬁ cantly, there is real public concern about the 
potential mental health effects of cannabis use, 
in particular the use of stronger forms of the drug, 
commonly known as skunk.’ 
So there was a skunk scare. Cannabis had gone from 
class B to C, but, supposedly, skunk use had been 
increasing and it was getting stronger, so we were 
asked to review whether the decision to go from B 
to C was still appropriate. The ACMD had produced 
two reports on cannabis in the previous ﬁ ve years 
(ACMD, 2002; Rawlins et al., 2005). These reports are 
very accessible and written in language that allows 
a lay person to understand the science as well as the 
policy implications. 
In our third cannabis report (Rawlins et al., 2008) we 
came to several conclusions: 
● Cannabis is a harmful drug and there are 
concerns about the widespread use of cannabis 
amongst young people.
● A concerted public health response is required 
to drastically reduce its use.
● Current evidence suggests a probable, but weak, 
causal link between psychotic illness and 
cannabis use. 
● The harms caused by cannabis are not considered 
to be as serious as drugs in class B and therefore it 
should remain a class C drug. 
Let me just guide you through some of the 
reasoning behind that ﬁ nal point. There has been 
a lot of commentary and some research as to 
whether cannabis is associated with schizophrenia, 
and the results are really quite difﬁ cult to interpret. 
What we can say is that cannabis use is associated 
with an increased experience of psychotic 
disorders. That is quite a complicated thing to 
disentangle because, of course, the reason people 
take cannabis is that it produces a change in their 
mental state. These changes are a bit akin to being 
psychotic – they include distortions of perception, 
especially in visual and auditory perception, as well 
as in the way one thinks. So it can be quite hard to 
know whether, when you analyse the incidence of 
psychotic disorders with cannabis, you are simply 
looking at the acute effects of cannabis, as opposed 
to some consequence of cannabis use. 
If we look on the generous side, there is a likelihood 
that taking cannabis, particularly if you use a lot of 
it, will make you more prone to having psychotic 
experiences. That includes schizophrenia, but 
schizophrenia is a relatively rare condition so it’s 
very hard to be sure about its causation. The analysis 
we came up with was that smokers of cannabis are 
about 2.6 times more likely to have a psychotic-like 
experience than non-smokers. To put that ﬁ gure 
in proportion, you are 20 times more likely to get 
lung cancer if you smoke tobacco than if you don’t. 
That’s the sort of scaling of harms that I want people 
to understand. There is a relatively small risk for 
smoking cannabis and psychotic illness compared 
with quite a substantial risk for smoking tobacco and 
lung cancer.  
The other paradox is that schizophrenia seems to 
be disappearing (from the general population) even 
though cannabis use has increased markedly in the 
last 30 years. When we were reviewing the general 
practice research database in the UK from the 
University of Keele, research consistently and clearly 
showed that psychosis and schizophrenia are still on 
the decline. So, even though skunk has been around 
now for ten years, there has been no upswing in 
schizophrenia. In fact, where people have looked, they 
haven’t found any evidence linking cannabis use in a 
population and schizophrenia.  
Another interesting ﬁ nding came from our analysis 
of what it would take to reduce the number of 
people being diagnosed with schizophrenia by 
targeting cannabis use. Our research estimates 
that, to prevent one episode of schizophrenia, we 
would need to stop about 5,000 men aged 20 to 
25 years from ever using the drug. This is obviously 
a major public health challenge and one that 
raises questions about whether it is a viable way of 
intervening with schizophrenia. So, overall, cannabis 
use does not lead to major health problems.  
We were also interested in the public perceptions of 
drugs. The public are often seen as major players in 
this debate, but we rarely ﬁ nd out exactly what the 
www.crimeandjustice.org.uk
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public thinks. In fact, the tendency is to assume that 
what the media produce is what the public think.  
In 2007, the government launched a consultation 
on a new drug strategy that included questions 
on cannabis to ﬁ nd out what the public thought. 
Two questions were asked: ‘Do you think cannabis 
should be reclassiﬁ ed?’ and ‘What are your views 
on tougher penalties?’ Responses from 639 people 
were obtained. Some responded on behalf of 
organisations and others responded individually.  
The responses are shown in Table 2, broken down 
into professional groups and personal responses. 
In the personal responses, the vast majority 
wanted cannabis to stay as class C, a significant 
number wanted it legalised, smaller numbers 
wanted it to go back up the classification scale 
and a reasonable number were undecided. Health 
professionals were more undecided.  Statutory 
partnerships were equally balanced between 
B and C, with the police strongly in favour of B. 
I should emphasise here that there is no direct 
benefit to the police in having cannabis classified 
as class B in terms of sentencing as both classes 
incur the same penalties. The majority of local 
authorities, drug service providers and charities 
wanted it to remain class C. Most respondents did 
not want to reclassify it to B.
The ACMD did not ﬁ nd the questions posed by 
the government consultation particularly helpful. 
We therefore carried out our own MORI survey of 
a representative general population sample as we 
were putting together this third report (Rawlins 
et al., 2008), and asked a couple of questions 
about cannabis. The ﬁ rst was what class should 
cannabis be?  Interestingly, what we found here 
was that just over half wanted it to be in a higher 
class (so a rather different response from that 
of the responders to the free question that the 
government put out) and about half wanted it to 
stay a C (see Table 3). This surprised us, as did the 
fact that 32 per cent wanted cannabis classiﬁ ed 
as class A. But the second question was the really 
interesting one: what should the penalties for 
possession be? Over two-thirds wanted them to 
either remain at current levels (class C) or to be 
lower (Table 4)! So, although a lot of people wanted 
cannabis class A, they didn’t want class A penalties.  
What you see here is an interesting ambivalence in 
the public mind: they want cannabis to be illegal 
(presumably because they think it is harmful, 
they want it class A or B) but they don’t want the 
penalties to be increased. If anything, many of 
them want the penalties abolished. It seemed to us 
that what the public appear to want is deterrence 
– they don’t want punishment; they want to scare 
people off cannabis use but they don’t want to 
punish them for using it. You may think that it is 
quite obvious that this is what the public wants but 
this is the ﬁ rst time we have had systematic data 
supporting this.  
Category of respondent Nos. 
Responding
Yes-Reclassify 
to ‘B’
No-Leave as ‘C’ Legalise Undecided
Health professionals 19 3 7 0 9
Statutory Partnerships 77 25 27 0 25
Policing Agencies 27 19 4 0 4
Local Authorities 50 13 22 0 15
Drug Service Providers 29 7 14 2 6
Charity & Voluntary 
Groups
23 4 9 1 9
Lobby/Activist/Pressure 
groups
15 2 7 3 3
Personal Responses 399 48 188 118 45
Total 639 121 278 124 116
TABLE 2 . PUBLIC OPINION ON CANNABIS-  GOVERNMENT POLL
Q39a. Do you think cannabis should be reclassiﬁ ed?
Q7. The Government is consulting on whether to make cannabis a Class B drug (it is currently Class C) which 
could mean tougher  penalties. What are your views?
www.crimeandjustice.org.uk
6
Media bias
I want to move on now to look at how people gather 
information about drugs and the challenges of 
communicating the best evidence relating to drug 
harms to the public. This is difﬁ cult in the face of what 
you might call a peculiar media imbalance in relation 
to drugs. The data in Table 5 illustrate a remarkable 
ﬁ nding. It derives from the PhD of a Scottish graduate, 
Alasdair J M Forsyth, who looked at every single 
newspaper report of drug deaths in Scotland from 
1990 to 1999 and compared them with the coroners’ 
data. 
Over the decade, there were 2,255 drug deaths, of 
which the Scottish newspapers reported 546. For 
aspirin, only one in every 265 deaths were reported 
– clearly aspirin was of no interest. For paracetamol, 
there was one newspaper report per 50 deaths, and 
for benzodiazepines (diazepam and temazepam) one 
in 15 to one in 50. For morphine, one in 72 deaths 
were reported, indicating that editors were not 
interested in this opiate. They were more interested in 
heroin, where one in ﬁ ve deaths were reported, and 
methadone where one in 16 deaths were reported. 
They were also more interested in stimulants. With 
amphetamines, deaths are relatively rare at 36, but 
one in three were reported; for cocaine it was one in 
eight. Amazingly, almost every single ecstasy death – 
that is, 26 out of 28 of those where ecstasy was named 
as a possible contributory factor – was reported. So 
there’s a peculiar imbalance in terms of reporting that 
is clearly inappropriate in relation to the relative harms 
of ecstasy compared with other drugs (Nutt et al., 
2009). The reporting gives the impression that ecstasy 
is a much more dangerous drug than it is. This is one 
of the reasons I wrote the article about horse riding 
that caused such extreme media reactions earlier 
this year (Nutt, 2009). The other thing you’ll notice is 
that there is a drug missing, and that’s cannabis. Also 
missing is alcohol, which will have killed a similar 
number, 2,000 to 3,000 people, in Scotland over that 
time, maybe more. Of course, cannabis wouldn’t have 
killed anyone because it doesn’t kill.  And that’s one of 
the reasons why we thought cannabis should be class 
C because you cannot die of cannabis overdose.  
The media are not alone in getting things wrong. 
It is very easy to get research money to show that 
drugs are harmful but it’s very hard to get research 
funds to show that they may not be so. A lot of 
Class A 32%
Class B 26%
Class C 18%
Legal 11%
Don’t know 13%
TABLE 3 . PUBLIC OPINION ON CANNABIS  ACMD
Ipsos- MORI poll conducted on befalf of the ACMD for the 2008 review of cannabis- 1003 respondents from the general public
Q. What class should cannabis be?
Class A 7yrs -11%
Class B 5yrs -13%
Class C 2yrs - 41%
No penalty 27%
Don’t know 8%
TABLE 4 . PUBLIC OPINION ON CANNABIS  ACMD
Ipsos- MORI poll conducted on befalf of the ACMD for the 2008 review of cannabis- 1003 respondents from the general public
Q. What should the penalty for possession be?
www.crimeandjustice.org.uk
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the scientiﬁ c reporting about drugs is biased. It’s a 
big challenge for scientists to make sure that their 
colleagues are producing data that are accurate. 
There have been some horriﬁ c examples where 
some of the so-called ‘top’ scientiﬁ c journals have 
published poor quality research about the harms 
of drugs such as cannabis or ecstasy, sometimes 
having to retract the articles. The problem is, you 
never see the retractions, you just see the front 
page of newspapers saying ‘ecstasy fries your brain’. 
The retraction explaining that methamphetamine 
rather than ecstasy was given by mistake is much 
less visible, if published at all! 
Drugs and politics
In 2008 the ACMD presented its third cannabis 
report in recent years to government and 
recommended that cannabis should remain a class 
C drug. The Home Secretary went on to discuss the 
report in parliament: 
‘In reaching my decision, I have also taken into 
account the views of others, particularly those 
responsible for enforcing the law, and the public … I 
have given the council’s report careful consideration. 
Of its 21 recommendations, I accept all bar those 
relating to classiﬁ cation …’ 
So why was that? The former Home Secretary 
continued:
 ‘My decision takes into account issues such as public 
perception and the needs and consequences for 
policing priorities. There is a compelling case for us to 
act now rather than risk the future health of young 
people. Where there is a clear and serious problem, 
but doubt about the potential harm that will be 
caused, we must err on the side of caution and 
protect the public. I make no apology for that. I am 
not prepared to wait and see.’ 
This issue of public perception is very important 
– and how best to have a sensible public debate 
and discussion about drug harms. As discussed 
above – and in our report – some members of the 
public might have wanted cannabis to move up a 
class but more wanted the penalties reduced, not 
even stay the same. We are producing reports based 
on detailed, extensive research, and the 2008 ACMD 
cannabis report (Rawlins et al., 2008) was one of 
the most detailed assessments of cannabis harms 
every done. We therefore really have a great deal of 
conﬁ dence in our analysis, as should the public and 
the government.
Drug Toxicological statistics (n) Newspaper reports (n) Toxicology to newspaper ratio
All cases 2255 546 4:1
Asprin/Salicylate 12 0 -
Paracetamol 265 1 265:1
Diazepam 481 10 48:1
Temazepam 369 25 15:1
Morphine 431 6 72:1
Amphetamines 36 13 3:1
Cocaine 30 4 8:1
Heroin/
Diamorphine
342 75 5:1
Methadone 460 29 16:1
Ecstasy/MDMAa 28 26 1:1
           
TABLE 5 . MEDIA BIAS
Distorted? a quantitative exploration of drug fatality reports in the popular press  
Alasdair J.M. Forsyth International Journal of Drug Policy 12 (2001) 435-453
...comparing ‘ofﬁ cial’ toxicological statistics for a single country (Scotland) with the reporting of drug deaths in that country’s 
most popular newspapers over a given time period (the 1990s)
www.crimeandjustice.org.uk
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The precautionary principle
So, one of the key arguments in moving cannabis 
from class C to B was the concern that skunk would 
cause more psychosis. What is very regularly invoked 
in this debate is the precautionary principle, which 
is that, if you’re not sure about a drug harm, rank 
it high, make all drugs class A and get rid of the 
problem. To repeat what the former Home Secretary 
said, ‘We must err on the side of caution and protect 
the public.’ As this is protection from the known 
unknowns, at ﬁ rst sight it might seem the obvious 
decision – why wouldn’t you take the precautionary 
principle? We know that drugs are harmful and that 
you can never evaluate a drug over the lifetime of a 
whole population, so we can never know whether, 
at some point in the future, a drug might lead to or 
cause more harm than it did early in its use.  
The precautionary principle is also an act of faith 
in deterrence, and this is one of the key issues for 
lawyers. However, it may end up doing more harm 
than one might assume. Does deterrence impact on 
drug use? We don’t know. In fact, the outcome may 
be the opposite of that predicted. It may be that if 
you move a drug up a class it has a greater cachet. 
People think, ‘Oh, it’s interesting, maybe we should be 
trying it because it’s a class B or a class A rather than 
a class C.’ We don’t know. We also don’t know what 
drives the use of drugs in relation to classiﬁ cation. 
More important, I think, the precautionary principle 
misleads. It starts to distort the value of evidence and 
therefore I think it could, and probably does, devalue 
evidence. This leads us to a position where people 
really don’t know what the evidence is. They see the 
classiﬁ cation, they hear about evidence and they 
get mixed messages. There’s quite a lot of anecdotal 
evidence that public conﬁ dence in the scientiﬁ c 
probity of government has been undermined in this 
kind of way.  
I will use MMR as an example of this process 
and the precautionary principle. People were 
concerned, on the basis of false science, that 
the triple vaccine might cause brain damage. 
This led to a reduction in vaccination uptake 
and now children are getting lung and brain 
damage from measles. In some circumstances, 
people accessed single vaccinations, which was 
more expensive, probably no safer, and in effect 
reduced the breadth of health protection across 
the community. The precautionary principle with 
MMR has been clearly shown to be wrong – it has 
harmed more people than it has helped. So we 
need to be very cautious about simply invoking 
the precautionary principle in relation to drugs.  
Another very sad example is that of a young woman 
from the Shetland Islands who died of a heroin 
overdose. Why was she taking heroin? The problem 
according to her friends was that she wanted, like her 
friends and other teenagers to try cannabis. In this 
isolated community it was, however, much easier to 
get heroin, presumably because it has a higher unit 
price and is easier and more proﬁ table to import than 
cannabis.  This is something we should bear in mind. 
We don’t know how many deaths are caused by a 
failure of people to access drugs that are relatively less 
dangerous because more dangerous drugs are being 
made available. Making all drugs class A would be a 
logical conclusion of the precautionary principle, but 
would be a supreme mistake.
Assessing harm
We’ve tried very hard for at least the last ten years 
to put together a structure for assessing drug 
harms. This began with the Runciman report 
(2000) and evolved into a more detailed analysis, 
which eventually turned into a research paper, 
‘Development of a rational scale to assess the harms 
of drugs of potential misuse’, published in The Lancet
(Nutt et al., 2007).  Despite – or perhaps because of 
– its novelty and remit, it was very hard to get the 
paper published because it challenged some of the 
current (mis)perceptions about drugs. 
In principle, we broke down drug harms into nine 
different parameters (Table 6). This system was 
arbitrary but we thought it was a sensible way of 
categorising all the possible harms from drugs, 
covering physical harms, dependence and social 
harms.  
We also looked at all the drugs in the MDA and 
added some others that weren’t already covered by 
the Act (Table 7). For example, we included ketamine, 
which wasn’t covered by the Act at the time, solvents, 
which are not included, and tobacco and alcohol, 
because we thought it was very important that 
harms of illicit drugs were assessed against the 
harms of drugs that people know and use, otherwise 
it is not possible to have a truly harm-based 
assessment. The scores of these other drugs also play 
an important part as anchor points against which 
others can be scaled. Without such reference points, 
the debate about relative drug harms becomes 
isolated and arbitrary, more akin to a ‘religious’ 
www.crimeandjustice.org.uk
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Physical Harm One Acute
Two Chronic
Three Intravenous harm
Dependence Four Intensity of pleasure
Five Psychological dependence
Six Physical dependence
Social Harms Seven Intoxication
Eight Other social harms
Nine Health-care costs
TABLE 6 . THE NINE PARAMETERS OF HARM
Parameter
From Nutt et al, 2007. Table 1: Assessment parameters
Class in Misuse of Drugs Act Comments
Ecstasy A Essentially 3,4-methylenedioxy-N-methylamphetamine 
(MDMA
4-MTA A 4-methylthioamphetamine
LSD A Lysergic acid diethylamid
Cocaine A Includes crack cocaine
Heroin A Crude diamorphine
Street methadone A Diverted prescribed methadone
Amphetamine B -
Methylphenidate B eg, Ritalin (methylphenidate)
Barbiturates B -
Buprenorphine C eg, Temgesic, Subutex
Benzodiazepines C eg, Valium (diazepam), Librium (chlordiazepoxide)
GHB C Gamma 4-hydroxybutyric acid
Anabolic steroids C -
Cannabis C -
Alcohol - Not controlled if over 18 years in UK
Alkylnitrites - Not controlled
Ketamine - Not controlled at the time of assessment; controlled as class 
C since
January, 2007
Khat - Not controlled
Solvents - Not controlled; sales restricted
Tobacco - Not controlled if over 16 years in UK
From Nutt et al, 2007. Table 2: The 20 substances assessed, showing their current status under the Misuse of Drugs Act
Note: Alcohol and tobacco are included here to give “anchor points”
TABLE 7 . THE DRUGS ASSESSED
www.crimeandjustice.org.uk
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discussion.  This analysis eventually established a 
ranking order presented in Figure 3. 
A number of important points emerged. The ranking 
suggested that there are clearly some very harmful 
drugs (you might say these would be class A drugs) 
and there are some drugs that aren’t very harmful, 
such as khat or alkylnitrites, which aren’t controlled 
by the Act at all. The dark bars are the class A drugs. 
Interestingly, some class A drugs scored much lower 
than other class A drugs, suggesting that there is 
some anomaly in terms of that part of the current 
statutory classiﬁ cation system.  
The ranking also suggests that a tripartite 
classiﬁ cation system might make sense, with drugs 
ranking as more harmful than alcohol being class A 
and those ranking lower than tobacco as class C. The 
exercise also highlighted how dangerous alcohol is. I 
believe that the challenges of dealing with the harms 
of alcohol is probably the biggest challenge that we 
have in relation to drug harms today.  
So, we used other drugs for a comparison of harms. 
But there are a lot of dangerous activities which 
society doesn’t necessarily discourage but does try 
to control. I believe that using analogies with other 
harmful activities helps us engage in appropriate 
debate about relative harms of drugs. One problem 
is that sometimes you get into what I think of as 
an illegality–logic loop. This is an example of a 
conversation that I’ve had many times with many 
people, some of them politicians:
MP: ‘You can’t compare harms from a legal activity 
with an illegal one.’
Professor Nutt: ‘Why not?’
MP: ‘Because one’s illegal.’ 
Professor Nutt: ‘Why is it illegal?’ 
MP: ‘Because it’s harmful.’ 
Professor Nutt: ‘Don’t we need to compare harms to 
determine if it should be illegal?’
MP:  ‘You can’t compare harms from a legal activity 
with an illegal one.’ 
repeats … 
I have been surprised how difﬁ cult this concept 
is to get across to some people, whether they are 
F IGURE 3 . DRUG HARM RANKING
Figure 1: Mean harm scores for 20 substances. 
The respective classiﬁ cation under the misuse of Drugs Act, where appropriate, is shown above each bar. Class A drugs are indicated by 
black bars, B by dark grey, and C by light grey. Unclassiﬁ ed substances are shown as unﬁ lled bars.
www.crimeandjustice.org.uk
11
politicians, fellow scientists or members of the 
general public. The supposition that if something is 
illegal its harms can’t be assessed in the same way as 
if it were legal is one that is quite difﬁ cult to break. A 
common corollary of this is that drug harms are seen 
as less acceptable than other harmful activities to 
non-users – though obviously a different attitude is 
taken by users. So who is right?
New drugs
Why is any of this important? Well we have other 
challenges. We have other drugs to review. I have 
mentioned GBL already, and you may know that there 
have been a couple of deaths recently from this strong 
sedative, which is chemically very similar to GHB 
but not currently controlled. Then there is ‘spice’ and 
related smoking mixtures. We didn’t know what these 
were until about six months ago, when there were 
some case reports of marked hallucinatory reactions 
to these mixtures. German chemists were able to 
analyse some of the herbal mixtures that produced 
these effects and discovered that the bulk comprised 
a pretty inert herb. However, it had been sprayed 
with synthetic cannabis agonists. These agonists are 
often more powerful than cannabis itself, so spice can 
be like smoking a potent form of cannabis. But it’s 
not controlled under the Act because, until now, the 
synthetic cannnabinoids have not been misused so 
they have never been controlled. This is something we 
are working on very hard at present to try to see if it’s 
possible to regulate or control them in the same way 
we control cannabis.  
Then there is the whole question of cognition 
enhancing drugs – so called ‘smart’ drugs. These are 
drugs, like modafanil (Provigil) and methylphenidate 
(Ritalin), which are used by students to help them 
work harder, stay up later to work, and sometimes to 
keep them awake when they want to go out partying 
all night. Should they be controlled? Do they cause 
harm? Are they likely to cause harm in the long term? 
These are the questions we are looking at.  
Classiﬁ cation of drugs in the Act
We also have to work on the classiﬁ cation 
conundrum: what are the boundaries between 
A, B and C? Can we come up with some absolute 
measures that would, in future, allow us to say this 
drug is A because of this or B because of this. One 
thing’s for sure: at present, experts and politicians 
don’t agree, which is why I think the public debate 
needs to begin. Who do the public trust more – the 
experts or the politicians? When we look at the 
discussion that we had about ecstasy (where the 
ACMD recommended class B (Nutt et al., 2009) and 
the government maintained it as A), I think there’s 
very little doubt that we, the scientists, won the 
intellectual argument, but we obviously didn’t win 
the decision in terms of classiﬁ cation. Any agreement 
will be difﬁ cult if we’re not talking in the same 
language about the same relative measures of harm; 
this is what I am trying to address in this talk.
A way forward?
I want to ﬁ nish by making a few suggestions. I think 
we need to improve the general understanding of 
relative harms. I think we need to educate people 
about drug harms in relation to the harms of other 
activities in life, so that it is possible for them to make 
sensible decisions about relative harms. One of the 
ways we are thinking of doing this is through using a 
technique called multicriteria decision-making. This 
approach has really come of age in helping solve 
another seriously difﬁ cult problem: nuclear waste 
disposal. A two-year open public consultation on this 
issue was conducted using multicriteria decision-
making. This not only takes into account the whole 
range of different criteria, but also formulates them 
in a way that gives speciﬁ c and agreed weights 
to each one. We didn’t do this in our drug harm 
assessments, or rather we haven’t done so as yet. 
In the case of nuclear waste, all the particular 
parameters of risk were worked through with 
the public as well as with experts so that the ﬁ nal 
weighting and ranking were truly a community 
decision. As a result of that massive consultation 
programme, it was decided that the future of nuclear 
waste was deep encasement underground. Thus, 
multicriteria decision-making is a proven technology, 
which I think could well be applied to something 
nearly as difﬁ cult as nuclear waste, drug harms.  
Another suggestion is that we should gather 
evidence about the impact of change of 
classiﬁ cation – something we are not routinely 
doing at present. We do not know the effects of 
downgrading cannabis from B to C. There was 
a fall in use but we do not know whether this 
was related to reclassiﬁ cation. The government 
doesn’t systematically carry out research on the 
consequences of changes in classiﬁ cation so we 
don’t know much about how classiﬁ cation systems 
impact on individuals’ desire to use or not to use a 
drug. This is a very important area of research for 
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social scientists and people interested in this aspect 
of legal science.  
I think we have to accept young people like to 
experiment – with drugs and other potentially 
harmful activities – and what we should be doing 
in all of this is to protect them from harm at this 
stage of their lives.  We therefore have to provide 
more accurate and credible information. If you 
think that scaring kids will stop them using, you’re 
probably wrong. They are often quite knowledgeable 
about drugs and the internet has made access to 
information extremely simple. We have to tell them 
the truth, so that they use us as their preferred 
source of information. A fully scientiﬁ cally-based 
Misuse of Drugs Act where drug classiﬁ cation 
accurately reﬂ ects harms would be a powerful 
educational tool. Using the Act in a political way to 
give messages other than those relating to relative 
harms undermines the Act and does great damage 
to the educational message.
We also have to fully endorse harm reduction 
approaches at all levels and especially stop the 
artiﬁ cial separation of alcohol and tobacco as 
‘non-drugs’. In some parts of the UK this has already 
happened. In Wales the programme of intervention 
in relation to drug harms now incorporates 
smoking and drinking because those are seen as 
in some cases being bigger problems than other 
drugs. There are other merits in approaching them 
simultaneously: for example, many of these drugs are 
being used at the same time by the same people.
Another key question we have to address as a society 
is whether our attitude to drugs is driven because of 
their harms or are we engaging in a moral debate? 
One thing this government has done extremely 
well in the last ten years is to cut away much of the 
moral argument about drug treatments. They have 
moved in the direction of improving access to harm 
reduction treatments, an approach that, I think, is 
wholly endorsed by the scientiﬁ c community and by 
the medical profession. For reasons that are not clear, 
the same evidence-based change has not happened 
in relation to the classiﬁ cation of drugs of misuse. 
I think it should happen because, while I’m not a 
moral philosopher, it seems to me difﬁ cult to defend 
a moral argument in relation to drugs if you don’t 
apply it to other equally harmful activities.  
Professor David Nutt, Imperial College London
Eve Saville Lecture, July 2009
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